| US 7,491,537 B2 | ||
| Nucleic acid formulations for gene delivery and methods of use | ||
| Jason G Fewell, The Woodlands, Tex. (US); Fiona MacLaughlin, Houston, Tex. (US); Louis C Smith, Houston, Tex. (US); Francois Nicol, Menlo Park, Calif. (US); and Alain Rolland, The Woodlands, Tex. (US) | ||
| Assigned to Genetronics Biomedical Corporation, San Diego, Calif. (US) | ||
| Filed on Nov. 20, 2006, as Appl. No. 11/561,847. | ||
| Application 11/561847 is a division of application No. 10/234406, filed on Sep. 03, 2002, granted, now 7,173,116. | ||
| Application 10/234406 is a continuation of application No. PCT/US01/06953, filed on Mar. 02, 2001. | ||
| Claims priority of provisional application 60/187236, filed on Mar. 03, 2000. | ||
| Claims priority of provisional application 60/261751, filed on Jan. 16, 2001. | ||
| Prior Publication US 2007/0213287 A1, Sep. 13, 2007 | ||
| Int. Cl. C12N 15/00 (2006.01); C12N 15/87 (2006.01); A61K 31/715 (2006.01); C07K 1/00 (2006.01) | ||
| U.S. Cl. 435—455 [435/461; 435/69.1; 435/320.1; 544/44; 530/300; 530/350] | 47 Claims |
| 1. A method of delivering a nucleic acid encoding a therapeutic gene product to a cell comprising:
introducing the nucleic acid encoding the therapeutic gene product to a cell in a formulation comprising the nucleic acid
formulated with an anionic polymer selected from the group consisting of: poly glutamic acid, poly aspartic acid, poly galacturonic
acid, poly vinyl sulfate, and co-polymers of glutamic and aspartic acid, and salts thereof,
wherein the anionic polymer is non-encapsulating and the formulation does not include a cationic polymer.
|